Bioventures 2018 L.P. Mpm Sells 3,733 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 3,733 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $7.01, for a total value of $26,168.33. Following the transaction, the insider directly owned 4,275,693 shares in the company, valued at approximately $29,972,607.93. This represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Up 0.3%

Shares of TRDA opened at $7.07 on Wednesday. The stock’s fifty day simple moving average is $7.08 and its 200-day simple moving average is $9.25. The firm has a market capitalization of $275.31 million, a PE ratio of -1.79 and a beta of -0.25. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares in the last quarter. Rhumbline Advisers raised its holdings in Entrada Therapeutics by 8.3% in the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after purchasing an additional 2,982 shares during the period. American Century Companies Inc. boosted its position in shares of Entrada Therapeutics by 10.8% during the second quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after purchasing an additional 7,301 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Entrada Therapeutics by 23.4% during the second quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after purchasing an additional 5,370 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Entrada Therapeutics by 34.2% in the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock valued at $150,000 after buying an additional 5,702 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TRDA shares. Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Roth Capital reissued a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Guggenheim reduced their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Finally, HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.